Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) will announce its fourth quarter and full-year 2021 financial results on March 1, 2022, after market close. The company will host a conference call at 4:30 p.m. E.T. to discuss these results and provide a corporate update. Interested parties can join the call by dialing specific numbers for domestic and international callers. Sarepta is focused on precision genetic medicine for rare diseases and has over 40 programs in development aimed at treating Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Positive

• Sarepta holds leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs).
• The company has over 40 programs in various stages of development.

Negative

• None.

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2021 financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 8075225. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2021 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com

FAQ

When will Sarepta Therapeutics report its Q4 2021 results?

Sarepta Therapeutics will report its fourth quarter and full-year 2021 financial results on March 1, 2022.

What time is the Sarepta earnings call scheduled?

The earnings call is scheduled for 4:30 p.m. E.T. on March 1, 2022.

How can I access the Sarepta Therapeutics earnings call?

The conference call can be accessed by dialing (844) 534-7313 for domestic or (574) 990-1451 for international callers, using passcode 8075225.

What does Sarepta Therapeutics focus on?

Sarepta Therapeutics focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy and limb-girdle muscular dystrophies.